differences were significant to a highly probable degree. Group 0 distribution was approximately the same in the two series. Further consideration of the small excess of group AB was deferred because of the relatively small numbers. The relative incidence of blood groups 0 and B compared with group A in patients with Parkinson's disease is given in Table II. The relative incidence of group B compared with group A was significantly greater than unity (P<0.05) and probably significant though not to a highly probable degree.
DIscussIoN
Woolf's method has been used to compare and combine these data with the Swedish figures as reported by Strang. The number of patients from Finland and Norway in Strang's paper was considered to be too small to be included in this analysis (Table IHI) . In Sweden the incidence of blood group 0 in patients with Parkinson's disease is significantly greater than that of blood group A. The Northern Ireland data reveal a low incidence of blood group A as compared with blood group 0, and a high incidence of group B in patients with Parkinson's disease. Combination of these two sets of data reveals a similar incidence ratio of Parkinson's disease in both the populations (O;:A). However, this is significant only in the Swedish series (P<0.01). Obviously further studies are needed in different geographical areas on similar lines before any deductions can be put forward. It is towards this end that the present study was undertaken.
SUMMARY
The ABO blood group distribution in 187 patients with Parkinson's disease in Northern Ireland showed a deficiency of blood group A and an excess of blood group B, when compared with the controls.
